Citamintab 50/850 mg (Sitagliptin Phosphate, Metformin Hydrochloride)
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Ilyon Pharmaceuticals Co., Ltd.
MFDS item code 201603081 · Approved 2016.05.30
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. The combination of sitagliptin and metformin acts together to effectively lower blood sugar levels and helps in managing blood glucose. Consequently, it reduces the risk of complications related to diabetes and helps maintain the patient’s health condition in a more stable manner.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral hypoglycemic agents. Any change in treatment for type 2 diabetes may result in changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is a diabetes treatment that contains sitagliptin and metformin, which helps control blood sugar levels. During use, severe allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or throat arise, discontinue use immediately and consult a doctor. There is a risk of acute pancreatitis, so if symptoms such as abdominal pain, nausea, vomiting, or loss of appetite occur, inform your healthcare provider promptly. Patients with severely impaired kidney function or at risk of acute kidney injury should not take this medication, and regular kidney function tests should be performed. Use of this medication should be avoided in conditions such as heart failure, severe infections, dehydration, or myocardial infarction. If undergoing iodine contrast tests, this medication should be halted for a certain period before and after the exam, and it should only be resumed after confirming normal kidney function. Pregnant or potentially pregnant women and breastfeeding mothers should not use this medication. This medication can cause hypoglycemia, so particularly when used with other antidiabetic agents such as insulin or sulfonylureas, blood sugar levels should be monitored frequently, and awareness of hypoglycemic symptoms is crucial. The metformin component can rarely cause a metabolic complication known as lactic acidosis, so if dehydration, severe infections, liver disease, or excessive alcohol intake occurs, discontinue use and consult a doctor. During treatment, if meal amounts are irregular or exercise levels increase suddenly, there is an increased risk of hypoglycemia, so caution is needed. Additionally, this medication may lead to vitamin B12 deficiency; thus, regular blood tests to check vitamin B12 levels are recommended for long-term use. If undergoing surgery, discontinue this medication 48 hours prior to the procedure and resume only after confirming normal kidney function post-surgery. The elderly are at a higher risk for decreased kidney function, so dosage adjustments and regular kidney function tests are necessary. Avoid alcohol consumption during treatment, and report any sudden symptoms or adverse reactions to your healthcare provider immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is best to maintain storage temperatures between 1 to 30 degrees Celsius. This will help preserve the drug's effectiveness and safety.
Pink oval film-coated tablet
30 tablets/box [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Ilyon Pharmaceuticals Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.